Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Commentary

Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship

Roger S. McIntyre, Jakub Z. Konarski, Sophie Grigoriadis, Nancy C. Fan, Deborah A. Mancini, Kari A. Fulton, Donna E. Stewart and Sidney H. Kennedy
CMAJ January 04, 2005 172 (1) 57-59; DOI: https://doi.org/10.1503/cmaj.1040517
Roger S. McIntyre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakub Z. Konarski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Grigoriadis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy C. Fan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah A. Mancini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kari A. Fulton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna E. Stewart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sidney H. Kennedy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 Canadian Medical Association or its licensors

Major depressive disorder is a prevalent and disabling condition.1 The causes of mood disorders are heterogeneous, involving a complicated interplay of both psychosocial and biological variables.2,3 In an analysis of adult women, the psychosocial variables that predicted major depression appeared to result from 3 broad pathways reflecting internalizing symptoms, externalizing symptoms and psychosocial adversity.4 In addition, there are significant associations between major depressive disorder and many chronic medical conditions (e.g., obesity, diabetes mellitus and hypothyroidism), underscoring the myriad biological variables that may be present in depression.5

Sex-related differences in mood disorders have been frequently reported6,7,8,9 and indicate the relevance of the reproductive endocrine system in the pathogenesis and treatment of mood disorders. For example, exacerbation of depressive symptoms and recurrence of depression in women with multiple-episode depression has been reported during perimenopause.10 The salutary neuropsychiatric effects of gonadal steroids are implicated yet not confirmed with extant data.11 Although the mechanism by which estrogen might attenuate depressive symptoms is unknown, mounting evidence indicates that estrogen influences neuronal function through monoaminergic- and GABAergic-mediated systems. Estrogen is also noted to inhibit monoamine oxidase activity.12,13,14

Preliminary data suggest that hormone replacement therapy (HRT) and antidepressant therapy may have overlapping molecular targets.15,16,17,18,19,20 Moreover, the putative antidepressant effects of HRT have also been reported.11,21,22,23,24,25,26,27,28,29 HRT has been prescribed for climacteric symptoms (e.g., vasomotor symptoms), and some antidepressants (e.g., serotonergic antidepressants) have been shown to alleviate the full range of climacteric symptoms.19,20,30 Thus, many women who experience depressive symptoms or a major depressive disorder at the time of menopause may find relief of these symptoms and even the disorder by using HRT.

With the publication in July 2002 of results indicating potential harmful effects of HRT (estrogen monotherapy), there was a dramatic reduction in HRT prescriptions. We hypothesized that the abrupt discontinuation of HRT would be associated with an increase in antidepressant usage. Fig. 1 appears to confirm the hypothesis.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 1: Top: Total estimated prescriptions dispensed in Ontario for hormone replacement therapy (HRT: oral and transdermal estrogen monotherapy and estrogen–progesterone combination therapy) and serotonergic antidepressants (SAs: citalopram, fluoxetine, sertraline, fluvoxamine, paroxetine, venlafaxine, nefazadone and trazadone) to women 45–65 years old, from January 2001 to June 2003. [Source: IMS Health Canada.] A consistent downward trajectory in the number of HRT prescriptions and a simultaneous increase in the number of SA prescriptions occurred after July 2002, when results indicating potential harmful effects of HRT were published. Bottom: Linear regression models of the number of prescriptions against time, for each prescription type (HRT and SA) and for each time period (11 months before and 11 months after July 2002). The predicted slopes (β ± standard error [prescriptions/day]) are shown, accompanied by a test of the null hypothesis: β = 0. There was no statistically significant longitudinal trend during the 11 months before July 2002; however, during the period following July 2002, there was a statistically significant decrease in HRT utilization that coincided with an increase in SA utilization. Comparison of the regression models (HRT v. SA prescriptions) revealed a statistically significant change in the prescription pattern of both agents after the medical scrutiny of HRT usage (β: –25.6 v. 33.2, p < 0.001). *p < 0.001.

We found that a significant decrease in the number of HRT prescriptions was associated with a statistically significant increase in prescriptions of serotonergic antidepressants. Others have noted associations between changes in HRT and antidepressant prescription patterns.17 The simultaneous increase in prescriptions of serotonergic antidepressants suggests that antidepressants are being prescribed for symptoms (psychological, physical) previously controlled with the use of HRT.19,20,30

With the diminished popularity of HRT, physicians may encounter women who are experiencing depressive symptoms or actual major depressive disorders that worsen at the time of menopause. A thorough assessment is encouraged for women who present during perimenopause with disabling psychological or somatic symptoms. Symptoms indicative of major depression include feelings of hopelessness, helplessness and worthlessness, suicidal ideation and anhedonia.

If patients are found to have major depressive disorder, as defined in the DSM-IV-TR,31 they should be offered pharmacotherapy, psychotherapy or both. If drug therapy is chosen, standard pharmacological agents are recommended, keeping in mind that serotonergic antidepressants are also effective against climacteric symptoms.32 Although there is a paucity of randomized controlled trials evaluating depression-specific psychotherapy (e.g., cognitive behavioural therapy) in perimenopausal women, cognitive behavioural therapy has been proven effective in the treatment of major depressive disorder, and it avoids the burden of drug-related adverse events.33 The Canadian Psychiatric Association recommends both medication and psychotherapy as first-line treatment of depressive disorders.33 Preference for either treatment modality is influenced by the severity of illness, the availability of treatment and patient preference.

In the interim, practitioners are encouraged to be vigilant for breakthrough psychiatric and climacteric symptoms in patients discontinuing HRT and to familiarize themselves with the beneficial effects of serotonergic antidepressants on climacteric symptoms.

Footnotes

  • Contributors: Roger McIntyre, Jakub Konarski and Kari Fulton contributed to the study conception and design, the data analysis and the manuscript production. Sophie Grigoriadis, Deborah Mancini, Donna Stewart and Sidney Kennedy contributed to the study conception and design and the manuscript production. Nancy Fan contributed to the conception and design of the article. All of the authors gave their final approval of the version submitted for publication.

    Acknowledgements: We thank Gary Fabian at IMS Health Canada for providing the prescription data.

    Competing interests: None declared for Jakub Konarski, Nancy Fan, Deborah Mancini or Kari Fulton. Roger McIntyre has received consultant and speaker fees from Astra Zeneca, Eli Lilly, Janssen-Ortho Pharmaceuticals, Organon, Wyeth Pharmaceuticals, Lundbeck, GlaxoSmithKline, ORYX Pharmaceuticals, Biovail Corporation and Pfizer Canada; he has received research funding from Wyeth Pharmaceuticals, GlaxoSmithKline, Merck and Servier. Sophie Grigoriadis has received research funding from Organon Canada, Merck, Eli Lilly and Jansen-Ortho Pharmaceuticals; she also received honoraria from Wyeth Pharmaceuticals. Donna Stewart has received research, consultant and speaker fees from Eli Lilly, and consultant and speaker fees from Wyeth Pharmaceuticals. Sidney Kennedy has received research funding from Janssen-Ortho Pharmaceuticals and Eli Lilly, and consultant fees from AstraZeneca, Biovail Corporation, Eli Lilly, Lundbeck, Servier, Wyeth Pharmaceuticals and Boehringer Ingelheim.

    Correspondence to: Dr. Roger S. McIntyre, Head, Mood Disorders Psychopharmacology Unit, University Health Network — Toronto Western Hospital, 399 Bathurst St., Toronto ON M5T 2S8; fax 416 603-5368; rmcintyruhnres.utoronto.ca

References

  1. 1.↵
    Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001;46(Suppl 1):5S-90S.
    OpenUrl
  2. 2.↵
    Bebbington P, Wilkins S, Sham P, Jones P, van Os J, Murray R, Toone B, Lewis S. Life events before psychotic episodes: Do clinical and social variables affect the relationship? Soc Psychiatry Psychiatr Epidemiol 1996;31(3-4):122-8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Bebbington P, Dunn G, Jenkins R, Lewis G, Brugha T, Farrell M, Meltzer H. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Int Rev Psychiatry 2003; 15(1-2):74-83.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in women. Am J Psychiatry 2002; 159 (7): 1133-45.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: Does cortisol play a role? Biol Psychiatry 2004;55(1):1-9.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Altshuler LL. The use of SSRIs in depressive disorders specific to women. J Clin Psychiatry 2002;63(Suppl 7):3-8.
    OpenUrl
  7. 7.↵
    Kornstein SG, Sloan DM, Thase ME. Gender-specific differences in depression and treatment response. Psychopharmacol Bull 2002;36(4 Suppl 3):99-112.
    OpenUrl
  8. 8.↵
    Grigoriadis S, Kennedy SH, Bagby RM. A comparison of antidepressant response in younger and older women. J Clin Psychopharmacol 2003;23(4):405-7.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Sloan DM, Kornstein SG. Gender differences in depression and response to antidepressant treatment. Psychiatr Clin North Am 2003;26(3):581-94.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Burt VK, Altshuler LL, Rasgon N. Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Harv Rev Psychiatry 1998;6 (3): 121-32.
    OpenUrlPubMed
  11. 11.↵
    Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, Rubinow DR. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183(2):414-20.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Kendall DA, Stancel GM, Enna SJ. The influence of sex hormones on antidepressant-induced alterations in neurotransmitter receptor binding. J Neurosci 1982; 2(3):354-60.
    OpenUrlAbstract
  13. 13.↵
    McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997;48(5 Suppl 7):S8-15.
  14. 14.↵
    Chakravorty SG, Halbreich U. The influence of estrogen on monoamine oxidase activity. Psychopharmacol Bull 1997;33(2):229-33.
    OpenUrlPubMed
  15. 15.↵
    Halbreich U, Kahn LS. Selective oestrogen receptor modulators--current and future brain and behaviour applications. Expert Opin Pharmacother 2000; 1 (7): 1385-98.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Winterhoff H, Spengler B, Christoffel V, Butterweck V, Lohning A. Cimicifuga extract BNO 1055: reduction of hot flushes and hints on antidepressant activity. Maturitas 2003;44(Suppl 1):S51-S58.
  17. 17.↵
    Reynolds RF, Walker AM, Obermeyer CM, Rahman O, Guilbert D. Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO. J Clin Epidemiol 2001;54(10):1056-64.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Weitzner MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002;23(4):337-45.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Stoppe G, Doren M. Critical appraisal of effects of estrogen replacement therapy on symptoms of depressed mood. Arch Women Ment Health 2002; 5 (2): 39-47.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289(21):2827-34.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Campbell S, Whitehead M. Oestrogens for menopausal flushing. BMJ 1977; 1 (6053): 104-5.
    OpenUrlFREE Full Text
  22. 22.↵
    Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 2000;157(6):924-30.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981;31(224):134-40.
    OpenUrlPubMed
  24. 24.↵
    Pearce J, Hawton K, Blake F, Barlow D, Rees M, Fagg J, Keenan J. Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study. J Psychosom Res 1997; 42(2):177-86.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995;102(6):475-84.
    OpenUrlPubMed
  26. 26.↵
    Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 1996; 347 (9006): 930-3.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 2003;160(8):1519-22.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Soares CN, Almeida OP, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58 (6):529-34.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Rasgon NL, Altshuler LL, Fairbanks L. Estrogen-replacement therapy for depression. Am J Psychiatry 2001;158(10):1738.
    OpenUrlCrossRefPubMed
  30. 30.↵
    Pinkerton JV, Santen R. Use of alternatives to estrogen for treatment of menopause. Minerva Endocrinol 2002;27(1):21-41.
    OpenUrlPubMed
  31. 31.↵
    Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington: American Psychiatric Association; 2000.
  32. 32.↵
    The North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11(1):11-33.
    OpenUrlCrossRefPubMed
  33. 33.↵
    Thorpe L, Whitney DK, Kutcher SP, Kennedy SH. Clinical guidelines for the treatment of depressive disorders. VI. Special populations. Can J Psychiatry 2001;46(Suppl 1):63S-76S.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (1)
CMAJ
Vol. 172, Issue 1
4 Jan 2005
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (127-138)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship
Roger S. McIntyre, Jakub Z. Konarski, Sophie Grigoriadis, Nancy C. Fan, Deborah A. Mancini, Kari A. Fulton, Donna E. Stewart, Sidney H. Kennedy
CMAJ Jan 2005, 172 (1) 57-59; DOI: 10.1503/cmaj.1040517

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship
Roger S. McIntyre, Jakub Z. Konarski, Sophie Grigoriadis, Nancy C. Fan, Deborah A. Mancini, Kari A. Fulton, Donna E. Stewart, Sidney H. Kennedy
CMAJ Jan 2005, 172 (1) 57-59; DOI: 10.1503/cmaj.1040517
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • HRT and antidepressants
  • HRT and antidepressants
  • Google Scholar

More in this TOC Section

  • Ensuring timely genetic diagnosis in adults
  • The case for improving the detection and treatment of obstructive sleep apnea following stroke
  • Laser devices for vaginal rejuvenation: effectiveness, regulation and marketing
Show more Commentary

Similar Articles

Collections

  • Topics
    • Psychiatry & mental health: adult
    • Women's health (including abortion)

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire